Sinovac Wins Approval in China for Streptococcus Pneumonia Vaccine

China’s Sinovac announced it has received approval from the China National Medical Products Administration for its streptococcus pneumonia vaccine meant to prevent infection in adults and children two years and older.

Approval was supported by a 2015 phase 3 study indicating the vaccine demonstrated positive safety and immunogenicity for 23 different disease serotypes or specific bacterial variations.

President and CEO Weidong Yin said that the product licensure allows Sinovac to “address unmet medical needs for the Chinese population,” and that this approval marks the company’s first for a bacterial vaccine.